ELI LILLY & CO
LLYNYSETrading Snapshot
- Day Range
- $1,196.97 – $1,225.36
- 52-Week Range
- $623.78 – $1,249.45
- Volume
- $15.27B
- Avg Volume
- $12.18B
- Shares Outstanding
- 941.7M
- Next Earnings
- Oct 5, 2026
Fundamentals Snapshot
- Annual Revenue
- $78.94B
- Last Q Revenue
- $19.33B
- P/E Ratio
- 42.2
- P/S Ratio
- 14.1x
- EPS (TTM)
- $29.80
- Dividend Yield
- 0.51%
Why Investors Own LLY
- ✓High-growth profile — revenue up -1.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 53% gross margin and 21% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ELI LILLY & CO
Pharma with leading GLP-1 franchise (Mounjaro, Zepbound).
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
ValuEngine Weekly Market Summary And Commentary
U.S. equity markets rebounded strongly this week, with gains led by technology and growth-oriented sectors.
Eli Lilly takes weight-loss pill battle global with first Foundayo approval in Europe
Lilly's Foundayo wins U.K. approval, taking its weight-loss pill battle with Novo Nordisk's Wegovy beyond the U.S. market.
Cramer’s Analyst Says Eli Lilly’s GLP-1 Stock Rally Has Years Left to Run
Jeff Marks and Jim Cramer say Eli Lilly's GLP-1 stock rally has years left, backed by surging global demand.
Eli Lilly (LLY) Stock Gets Fair Value Bump After GLP 1 Driven Analyst Revisions
Eli Lilly’s updated fair value price target has shifted from US$1,270.37 to US$1,297.31, giving investors a fresh reference point for how analysts are framing the stock today. Much of this reset is tied to recent Street commentary that focuses on incretin and GLP-1 therapies, Q2 results, and the potential of assets like Mounjaro, Zepbound, retatrutide and Foundayo. As you read on, you will see how to track these moving parts and keep up with the evolving Eli Lilly narrative. Stay updated as...
What Analysts Really Pressed LLY On This Quarter
Eli Lilly's growth is huge, but on its latest call, analysts tested whether the next chapter can possibly live up to the last one.
Eli Lilly vs. Novo Nordisk: Which Company Is Better Positioned for America’s New Drug Manufacturing Policies?
For years, investors have viewed Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) through one lens: the race to dominate the booming obesity-drug market. But Washington is beginning to shift the conversation. With the U.S. government pushing pharmaceutical companies to manufacture more medicines domestically and reduce dependence on overseas supply chains, manufacturing has become more of […]